
Palatin Investor Relations Material
Latest events

Q2 2025
Palatin
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Palatin Technologies Inc
Access all reports
Segment Data
Access more data
Revenue by
Source
Product revenue, net
License and contract
Expenses by
Financials
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The Company's lead product candidate is bremelanotide, which is under review by the U.S. Food and Drug Administration (FDA) for the potential treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women; and the treatment of benign prostatic hyperplasia (BPH) in men. The Company has its U.S.-based headquarters and research facility located in Cranbury, New Jersey.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
PTN
Country
🇺🇸 United States